Table 1 Description of participants according to the type of vaccine inoculated.

N

277

165

162

73

32

709

Age, mean (SD)

45 (10.9)

45.5 (11.9)

43.9 (10.7)

40.2 (10.4)

41.6 (12.0)

44.2 (11.2)

Women (%)

87.7

85.5

85.2

79.5

90.6

85.9

% Previous COVID-19

9.2%

43.1%

0.8%

0%

76%

17.2%

Anti-S-RBD U/mL median (IQR) COVID-19 infected individuals

1 dose

21-days follow-up

20,145 (7450–27,473)

15,659 (10,448–22,027)

–

–

5344 (458–9550)

12,374 (6936–21,695)

2 doses^a

21-days follow-up

21,028 (9408–31,997)

21,433 (15,412–30,064)

–

3546 (968–4141)

3092 (1113–5353)

15,800 (4390–26,014)

2 doses^a

3-months follow-up

6711 (3814–12,119)

9800 (6631–15,948)

–

1544 (877–12,389)

2677 (1689–5769)

6902 (3098–11,256)

2 doses^a

6-months follow-up

3217 (1650–4781)

3900 (2664–6234)

–

1456 (404–8807)

1465 (799–3413)

3141 (1578–4985)

2 doses^a

9-months follow-up

1517 (851–3009)

2291 (1523–4958)

–

–

1222 (651–2342)

1926 (1041–4315)

Anti-S-RBD U/mL median (IQR) COVID-19 non-infected individuals

1 dose

21-days follow-up

119.7 (49.9–193.9)

46 (17.4–96.6)

32 (13.8–68.2)

–

49.4 (22.1–123.2)

2 doses

21-days follow-up

4295 (2763–6203)

1959 (1221–3712)

2230 (1201–3667)

12,380 (8152–18,434)

–

3499 (1862–6185)

2 doses

3-months follow-up

2416 (1496–3736)

1336 (899.8–2065)

900 (570–1665)

3452 (2043–4616)

–

1758 (981.7–3173)

2 doses

6-months follow-up

1332 (970–2135)

805 (447–1118)

429 (272–757)

1370 (691–1882)

–

1004 (491–1595)

2 doses

9-months follow-up

674 (448–1093)

510,3 (267–758)

–

–

–

635 (397–971)

% COVID-19 Infection (Anti-N > 0.150 COI) after 2nd dose

21-days follow-up

9.2%

43.1%

0.8%

0%

88%

18%

3-months follow-up

9.8%

42.2%

3.1%

0%

92%

19.3%

6-months follow-up

12.4%

43.1%

3.8%

0%

92%

20.5%

9-months follow-up

14.4%

42.2%

–

–

92%

31.9%